Thermo Fisher Scientific Inc. (NYSE: TMO) has a price-to-earnings ratio of 37.53x that is above its average ratio. Additionally, the 36-month beta value for TMO is 0.80. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 8 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for TMO is 381.00M and currently, short sellers hold a 0.73% ratio of that float. The average trading volume of TMO on May 24, 2024 was 1.35M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TMO) stock’s latest price update
Thermo Fisher Scientific Inc. (NYSE: TMO)’s stock price has decreased by -0.98 compared to its previous closing price of 590.80. However, the company has seen a -2.03% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2024-05-23 that Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.
TMO’s Market Performance
Thermo Fisher Scientific Inc. (TMO) has experienced a -2.03% fall in stock performance for the past week, with a 1.32% rise in the past month, and a 3.60% rise in the past quarter. The volatility ratio for the week is 1.29%, and the volatility levels for the past 30 days are at 1.51% for TMO. The simple moving average for the past 20 days is 0.41% for TMO’s stock, with a 9.72% simple moving average for the past 200 days.
Analysts’ Opinion of TMO
Many brokerage firms have already submitted their reports for TMO stocks, with Citigroup repeating the rating for TMO by listing it as a “Neutral.” The predicted price for TMO in the upcoming period, according to Citigroup is $620 based on the research report published on March 18, 2024 of the current year 2024.
Barclays, on the other hand, stated in their research note that they expect to see TMO reach a price target of $555, previously predicting the price at $475. The rating they have provided for TMO stocks is “Equal Weight” according to the report published on January 24th, 2024.
TMO Trading at 1.46% from the 50-Day Moving Average
After a stumble in the market that brought TMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.11% of loss for the given period.
Volatility was left at 1.51%, however, over the last 30 days, the volatility rate increased by 1.29%, as shares surge +2.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.40% lower at present.
During the last 5 trading sessions, TMO fell by -2.03%, which changed the moving average for the period of 200-days by +5.26% in comparison to the 20-day moving average, which settled at $583.29. In addition, Thermo Fisher Scientific Inc. saw 10.22% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMO starting from Lagarde Michel, who sale 20,000 shares at the price of $590.05 back on May 14 ’24. After this action, Lagarde Michel now owns 18,134 shares of Thermo Fisher Scientific Inc., valued at $11,801,000 using the latest closing price.
Williamson Stephen, the Sr. VP and CFO of Thermo Fisher Scientific Inc., sale 21,925 shares at $591.27 during a trade that took place back on May 13 ’24, which means that Williamson Stephen is holding 36,482 shares at $12,963,595 based on the most recent closing price.
Stock Fundamentals for TMO
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.41 for the gross margin
The net margin for Thermo Fisher Scientific Inc. stands at 0.14. The total capital return value is set at 0.08. Equity return is now at value 13.75, with 6.29 for asset returns.
Based on Thermo Fisher Scientific Inc. (TMO), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.25. The debt to equity ratio resting at 0.78. The interest coverage ratio of the stock is 10.66.
Currently, EBITDA for the company is 10.72 billion with net debt to EBITDA at 2.93. When we switch over and look at the enterprise to sales, we see a ratio of 5.96. The receivables turnover for the company is 4.54for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.70.
Conclusion
In conclusion, Thermo Fisher Scientific Inc. (TMO) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
